scPharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to include treatment of edema in patients with chronic kidney disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH: